These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33330677)

  • 1. Sacubitril/Valsartan: Potential Impact of ARNi "Beyond the Wall" of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19.
    Rubattu S; Gallo G; Volpe M
    Front Cardiovasc Med; 2020; 7():616564. PubMed ID: 33330677
    [No Abstract]   [Full Text] [Related]  

  • 2. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study.
    Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
    Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
    Niu CY; Yang SF; Ou SM; Wu CH; Huang PH; Hung CL; Lin CC; Li SY
    J Am Heart Assoc; 2022 Sep; 11(18):e026407. PubMed ID: 36062622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in pulmonary artery pressures with use of sacubitril/valsartan.
    De Simone V; Guarise P; Zanotto G; Morando G
    J Cardiol Cases; 2019 Nov; 20(5):187-190. PubMed ID: 31719942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
    Lelonek M; Wiśniowska-Śmiałek S; Rubiś P; Nowakowska I; Pawlak A
    Adv Clin Exp Med; 2021 Jan; 30(1):67-75. PubMed ID: 33529509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
    Codina P; Domingo M; Barceló E; Gastelurrutia P; Casquete D; Vila J; Abdul-Jawad Altisent O; Spitaleri G; Cediel G; Santiago-Vacas E; Zamora E; Ruiz-Cueto M; Santesmases J; de la Espriella R; Pascual-Figal DA; Nuñez J; Lupón J; Bayes-Genis A
    ESC Heart Fail; 2022 Aug; 9(4):2170-2180. PubMed ID: 35588235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Miura M; Kondo M; Sato K; Endo H
    BMC Cardiovasc Disord; 2023 Jan; 23(1):39. PubMed ID: 36681789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
    Okutucu S; Sabanoglu C; Yetis Sayin B; Aksoy H; Bursa N; Oto A
    Acta Cardiol; 2020 Feb; 75(1):20-25. PubMed ID: 30513267
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
    Dewan P; Docherty KF; McMurray JJV
    Korean Circ J; 2019 Jun; 49(6):469-484. PubMed ID: 31172710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review.
    Pascual-Figal D; Bayés-Genis A; Beltrán-Troncoso P; Caravaca-Pérez P; Conde-Martel A; Crespo-Leiro MG; Delgado JF; Díez J; Formiga F; Manito N
    Front Cardiovasc Med; 2021; 8():754499. PubMed ID: 34859070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
    Maggioni AP; Clark AL; Barrios V; Damy T; Drozdz J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Zeymer U;
    ESC Heart Fail; 2022 Dec; 9(6):4209-4218. PubMed ID: 36106548
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.